Muscle cell survival mediated by the transcriptional coactivators p300 and PCAF displays different requirements for acetyltransferase activity

American Journal of Physiology - Cell Physiology

Volumn 291, Issue 4, 2006, Pages

  Kuninger, David ^a   Wright, Alistair ^a,c   Rotwein, Peter ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Fibroblast growth factor I; Microarray; Myoblast

Indexed keywords

ACYLTRANSFERASE; FIBROBLAST GROWTH FACTOR 1; HISTONE ACETYLTRANSFERASE PCAF; MYOD PROTEIN; PROTEIN P300;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE IDENTIFICATION; GENE INDUCTION; HUMAN; MICROARRAY ANALYSIS; MOUSE; MUSCLE CELL; MYOBLAST; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

ACETYLTRANSFERASES; ANIMALS; CELL CYCLE PROTEINS; CELL SURVIVAL; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; E1A-ASSOCIATED P300 PROTEIN; FIBROBLAST GROWTH FACTOR 1; GENE EXPRESSION REGULATION; HISTONE ACETYLTRANSFERASES; HUMANS; MICE; MYOBLASTS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, FIBROBLAST GROWTH FACTOR; TRANSCRIPTION FACTORS;

EID: 33749424172     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00056.2006     Document Type: Article

References (60)

1. Barton ER, Morris L, Musaro A, Rosenthal N, and Sweeney HL. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 157: 137-148, 2002.
2. Black BL and Olson EN. Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu Rev Cell Dev Biol 14: 167-196, 1998.
3. Buckingham M, Bajard L, Chang T, Daubas P, Hadchouel J, Meilhac S, Montarras D, Rocancourt D, and Relaix F. The formation of skeletal muscle: from somite to limb. J Anat 202: 59-68, 2003.
4. Buehler A, Martire A, Strohm C, Wolfram S, Fernandez B, Palmen M, Wehrens XH, Doevendans PA, Franz WM, Schaper W, and Zimmermann R. Angiogenesis- independent cardioprotection in FGF-1 transgenic mice. Cardiovasc Res 55: 768-777, 2002.
5. Chen YW, Hubal MJ, Hoffman EP, Thompson PD, and Clarkson PM. Molecular responses of human muscle to eccentric exercise. J Appl Physiol 95: 2485-2494, 2003.
6. Cheng J, Sun S, Tracy A, Hubbell E, Morris J, Valmeekam V, Kimbrough A, Cline MS, Liu G, Shigeta R, Kulp D, and Siani-Rose MA. NetAffx Gene Ontology Mining Tool: a visual approach for microarray data analysis. Bioinformatics 20: 1462-1463, 2004.
7. Coolican SA, Samuel DS, Ewton DZ, McWade FJ, and Florini JR. The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem 272: 6653-6662, 1997.
8. Cuevas P, Carceller F, Reimers D, and Gimenez-Gallego G. Fibroblast growth factor-1 inhibits medial smooth muscle cells apoptosis after balloon injury. Neurol Res 22: 185-188, 2000.
9. Cuevas P, Reimers D, Carceller F, Martinez-Coso V, Redondo-Horcajo M, Saenz de Tejada I, and Gimenez-Gallego G. Fibroblast growth factor-1 prevents myocardial apoptosis triggered by ischemia reperfusion injury. Eur J Med Res 2: 465-468, 1997.
10. Datta SR, Brunet A, and Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927, 1999.
11. Eckner R, Yao TP, Oldread E, and Livingston DM. Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation. Genes Dev 10: 2478-2490, 1996.
12. Fu XB, Li XK, Wang T, Cheng B, and Sheng ZY. Enhanced anti-apoptosis and gut epithelium protection function of acidic fibroblast growth factor after cancelling of its mitogenic activity. World J Gastroenterol 10: 3590-3596, 2004.
13. Goetsch SC, Hawke TJ, Gallardo TD, Richardson JA, and Garry DJ. Transcriptional profiling and regulation of the extracellular matrix during muscle regeneration. Physiol Genomics 14: 261-271, 2003.
14. Goodman RH and Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev 14: 1553-1577, 2000.
15. Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R, Eilbeck K, Lewis S, Marshall B, Mungall C, Richter J, Rubin GM, Blake JA, Bult C, Dolan M, Drabkin H, Eppig JT, Hill DP, Ni L, Ringwald M, Balakrishnan R, Cherry JM, Christie KR, Costanzo MC, Dwight SS, Engel S, Fisk DG, Hirschman JE, Hong EL, Nash RS, Sethuraman A, Theesfeld CL, Botstein D, Dolinski K, Feierbach B, Berardini T, Mundodi S, Rhee SY, Apweiler R, Barrell D, Camon E, Dimmer E, Lee V, Chisholm R, Gaudet P, Kibbe W, Kishore R, Schwarz EM, Sternberg P, Gwinn M, Hannick L, Wortman J, Berriman M, Wood V, de la Cruz N, Tonellato P, Jaiswal P, Seigfried T, and White R. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res 32: D258-D261, 2004.
16. Hirata A, Masuda S, Tamura T, Kai K, Ojima K, Fukase A, Motoyoshi Kamakura K, K, Miyagoe-Suzuki Y, and Takeda S. Expression profiling of cytokines and related genes in regenerating skeletal muscle after cardiotoxin injection: a role for osteopontin. Am J Pathol 163: 203-215, 2003.
17. Horuk R. Chemokine receptors. Cytokine Growth Factor Rev 12: 313-335, 2001.
18. Kaliman P, Vinals F, Testar X, Palacin M, and Zorzano A. Phosphatidylinositol 3-kinase inhibitors block differentiation of skeletal muscle cells. J Biol Chem 271: 19146-19151, 1996.
19. Kalkhoven E. CBP and p300: HATs for different occasions. Biochem Pharmacol 68: 1145-1155, 2004.
20. Kawasaki H, Eckner R, Yao TP, Taira K, Chiu R, Livingston DM, and Yokoyama KK. Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature 393: 284-289, 1998.
21. Kennedy SG, Kandel ES, Cross TK, and Hay N. Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol 19: 5800-5810, 1999.
22. Kovalenko D, Yang X, Nadeau RJ, Harkins LK, and Friesel R. Sef inhibits fibroblast growth factor signaling by inhibiting FGFR1 tyrosine phosphorylation and subsequent ERK activation. J Biol Chem 278: 14087-14091, 2003.
23. Kraus WL, Manning ET, and Kadonaga JT. Biochemical analysis of distinct activation functions in p300 that enhance transcription initiation with chromatin templates. Mol Cell Biol 19: 8123-8135, 1999.
24. Kung AL, Rebel VI, Bronson RT, Ch'ng LE, Sieff CA, Livingston DM, and Yao TP. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev 14: 272-277, 2000.
25. Lawlor MA, Feng X, Everding DR, Sieger K, Stewart CE, and Rotwein P. Dual control of muscle cell survival by distinct growth factor-regulated signaling pathways. Mol Cell Biol 20: 3256-3265, 2000.
26. Lawlor MA and Rotwein P. Insulin-like growth factor-mediated muscle cell survival: central roles for Akt and cyclin-dependent kinase inhibitor p21. Mol Cell Biol 20: 8983-8995, 2000.
27. Lawlor MA and Rotwein P. Coordinate control of muscle cell survival by distinct insulin-like growth factor activated signaling pathways. J Cell Biol 151: 1131-1140, 2000.
28. Liu JP, Baker Perkins J, AS, Robertson EJ, and Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75: 59-72, 1993.
29. Ma K, Chan JK, Zhu G, and Wu Z. Myocyte enhancer factor 2 acetylation by p300 enhances its DNA binding activity, transcriptional activity, and myogenic differentiation. Mol Cell Biol 25: 3575-3582, 2005.
30. McKinsey TA, Zhang CL, and Olson EN. Signaling chromatin to make muscle. Curr Opin Cell Biol 14: 763-772, 2002.
31. Nakae J, Kido Y, and Accili D. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 22: 818-835, 2001.
32. Ng HH and Bird A. Histone deacetylases: silencers for hire. Trends Biochem Sci 25: 121-126, 2000.
33. Paul AC and Rosenthal N. Different modes of hypertrophy in skeletal muscle fibers. J Cell Biol 156: 751-760, 2002.
34. Perry RL and Rudnicki MA. Molecular mechanisms regulating myogenic determination and differentiation. Front Biosci 5: D750-D767, 2000.
35. Polesskaya A and Harel-Bellan A. Acetylation of MyoD by p300 requires more than its histone acetyl-transferase domain. J Biol Chem 276: 44502-44503, 2001.
36. Polesskaya A, Naguibneva I, Duquet A, Bengal E, Robin P, and Harel-Bellan A. Interaction between acetylated MyoD and the bromodomain of CBP and/or p300. Mol Cell Biol 21: 5312-5320, 2001.
37. Powell-Braxton L, Hollingshead P, Warburton C, Dowd M, Pitts-Meek S, Dalton D, Gillett N, and Stewart TA. IGF-I is required for normal embryonic growth in mice. Genes Dev 7: 2609-2617, 1993.
38. Powers CJ, McLeskey SW, and Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7: 165-197, 2000.
39. Puri PL, Sartorelli V, Yang XJ, Hamamori Y, Ogryzko VV, Howard BH, Kedes L, Wang JY, Graessmann A, Nakatani Y, and Levrero M. Differential roles of p300 and PCAF acetyl-transferases in muscle differentiation. Mol Cell 1: 35-45, 1997.
40. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD, and Glass DJ. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 3: 1009-1013, 2001.
41. Roth JF, Shikama N, Henzen C, Desbaillets I, Lutz W, Marino S, Wittwer J, Schorle H, Gassmann M, and Eckner R. Differential role of p300 and CBP acetyl-transferase during myogenesis: p300 acts upstream of MyoD and Myf5. EMBO J 22: 5186-5196, 2003.
42. Sabourin LA and Rudnicki MA. The molecular regulation of myogenesis. Clin Genet 57: 16-25, 2000.
43. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, and Goldberg AL. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117: 399-412, 2004.
44. Sartorelli V, Huang J, Hamamori Y, and Kedes L. Molecular mechanisms of myogenic coactivation by p300: direct interaction with the activation domain of MyoD and with the MADS box of MEF2C. Mol Cell Biol 17: 1010-1026, 1997.
45. Sartorelli V, Puri PL, Hamamori Y, Ogryzko V, Chung G, Nakatani Y, Wang JY, and Kedes L. Acetylation of MyoD directed by PCAF is necessary for the execution of the muscle program. Mol Cell 4: 725-734, 1999.
46. Schreiber E, Matthias P, Muller MM, and Schaffner W. Rapid detection of octamer binding proteins with "mini-extracts", prepared from a small number of cells. Nucleic Acids Res 17: 6419, 1989.
47. Stewart CE and Rotwein P. Insulin-like growth factor-II is an autocrine survival factor for differentiating myoblasts. J Biol Chem 271: 11330-11338, 1996.
48. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, and Glass DJ. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14: 395-403, 2004.
49. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 12: 599-606, 1998.
50. Summan M, McKinstry M, Warren GL, Hulderman T, Mishra D, Brumbaugh K, Luster MI, and Simeonova PP. Inflammatory mediators and skeletal muscle injury: a DNA micro-array analysis. J Interferon Cytokine Res 23: 237-245, 2003.
51. Wan X, Nass P, Duncan MD, and Harmon JW. Acidic fibroblast growth factor overexpression partially protects 3T3 fibroblasts from apoptosis induced by synthetic retinoid CD437. J Mol Med 79: 143-148, 2001.
52. Wang L, Liu L, and Berger SL. Critical residues for histone acetylation by Gcn5, functioning in Ada and SAGA complexes, are also required for transcriptional function in vivo. Genes Dev 12: 640-653, 1998.
53. Warren GL, Hulderman T, Mishra D, Gao X, Millecchia L, O'Farrell L, Kuziel WA, and Simeonova PP. Chemokine receptor CCR2 involvement in skeletal muscle regeneration. FASEB J 19: 413-415, 2005.
54. Warren GL, O'Farrell L, Summan M, Hulderman T, Mishra D, Luster MI, Kuziel WA, and Simeonova PP. Role of CC chemokines in skeletal muscle functional restoration after injury. Am J Physiol Cell Physiol 286: C1031-C1036, 2004.
55. Wilson EM, Hsieh MM, and Rotwein P. Autocrine growth factor signaling by insulin-like growth factor-II mediates MyoD-stimulated myocyte maturation. J Biol Chem 278: 41109-41113, 2003.
56. Woelfle J, Billiard J, and Rotwein P. Acute control of insulin-like growth factor-I gene transcription by growth hormone through Stat5b. J Biol Chem 278: 22696-22702, 2003.
57. Yang XJ. Lysine acetylation and the bromodomain: a new partnership for signaling. Bioessays 26: 1076-1087, 2004.
58. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, and Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382: 319-324, 1996.
59. Yao TP, Oh SP, Fuchs M, Zhou ND, Ch'ng LE, Newsome D, Bronson RT, Li E, Livingston DM, and Eckner R. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93: 361-372, 1998.
60. Zlotnik A and Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 12: 121-127, 2000.